Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av BBT001 hos friske frivillige (HVS) og hos voksne pasienter med atopisk dermatitt (AD)

26. september 2026 oppdatert av: Bambusa Therapeutics

En randomisert, blendet, placebokontrollert, en- og flerfast-dose-studie for å evaluere sikkerhet, tolerabilitet, farmakokinetikk, immunogenisitet, farmakodynamikk og klinisk aktivitet av BBT001 hos HVS og AD-pasienter

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.

Studietype

Intervensjonell

Registrering (Antatt)

237

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Western Australia
      • Fremantle, Western Australia, Australia, 6160
        • Rekruttering
        • Fremantle Dermatology
      • Perth, Western Australia, Australia, 6009
        • Fullført
        • Linear Clinical Research
    • California
      • Irvine, California, Forente stater, 92614
        • Rekruttering
        • First OC Dermatology
    • New York
      • New York, New York, Forente stater, 10128
        • Rekruttering
        • OptiSkin Medical
      • The Bronx, New York, Forente stater, 10455
        • Rekruttering
        • Equity Medical, LLC
      • Christchurch, New Zealand
        • Rekruttering
        • Optimal Clinical Trials Ltd - Christchurch
      • Upper Hutt, New Zealand, 5018
        • Rekruttering
        • Pacific Clinical Research Network (PCRN) Wellington
        • Ta kontakt med:
          • Tim Humphrey
    • Auckland
      • Grafton, Auckland, New Zealand, 1010
        • Rekruttering
        • Optimal Clinical Trials Central Auckland
        • Ta kontakt med:
          • Arna Letica
      • Otahuhu, Auckland, New Zealand, 2025
        • Tilbaketrukket
        • Aotearoa Clinical Trials
      • Takapuna, Auckland, New Zealand, 0622
        • Rekruttering
        • Pacific Clinical Research Network (PCRN) - Auckland
        • Ta kontakt med:
          • Paul Hamilton
      • Lodz, Polen, 91-347
        • Rekruttering
        • Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
      • Rzeszów, Polen, 35-055
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
      • Warsaw, Polen, 02-507
        • Rekruttering
        • Państwowy Instytut Medyczny MSWiA
      • Wroclaw, Polen, 50-566
        • Rekruttering
        • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 72 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria

  1. Negative pregnancy tests for women of childbearing potential.
  2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
  3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
  4. Adequate contraception use (for men and women of childbearing potential).

Key Inclusion Criteria (Parts A, B, and D)

  1. Age of 18-65 years.
  2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
  3. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Parts C and E only)

  1. Age of 18-72 years.
  2. Body mass index ≥16 kg/m², weight capped at 125 kg.
  3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
  4. Moderate to severe atopic dermatitis
  5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
  6. Atopic lesions cover ≥10% of body surface area (BSA)
  7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Key Exclusion Criteria

  1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
  2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
  3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
  4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
  5. Abnormal Electrocardiogram (ECG) findings
  6. History of drug/alcohol abuse in the past 2 years.
  7. Donated >500mL blood within 2 months of screening.
  8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria (Parts A, B, and D only)

1. History of atopic dermatitis

Key Exclusion Criteria (Parts C and E only)

  1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
  2. Receipt of immunoglobulin or blood products within 30 days.
  3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
  4. Chronic pruritus from conditions other than atopic dermatitis.
  5. Acute/treated infections or chronic skin infections.
  6. Current use of sedating antihistamines or corticosteroids.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part A Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Eksperimentell: Part B Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in healthy volunteers.

BBT001 will be administered

Eksperimentell: Part C Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo komparator: Part A Single Ascending Dose Placebo

A single dose of Placebo will be administered in healthy volunteers

Placebo will be administered

Placebo komparator: Part B Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in healthy volunteers.

Placebo will be administered

Placebo komparator: Part C Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Aktiv komparator: Part D Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Placebo komparator: Part D Single Ascending Dose Placebo

A single dose of placebo will be administered in healthy volunteers

Placebo will be administered

Aktiv komparator: Part E Multiple Ascending Dose BBT001 - Dose Level 1

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo komparator: Part E Multiple Ascending Dose Placebo

Multiple doses of placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Aktiv komparator: Part E Multiple Ascending Dose BBT001 - Dose Level 2

Multiple doses of BBT001 will be administered in patients with atopic dermatitis

BBT001 will be administered

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with adverse events following single and multiple administration of BBT001
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in serum blood parameters
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Laboratory assessments include hematology, blood chemistry and coagulation test

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in vital sign measurements following treatment administration.
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Blood pressure and heart rate will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in physical examination following treatment administration.
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Physical examination will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in 12-lead ECG readings
Tidsramme: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

12-lead ECG will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Maximum observed concentration of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum PK Tmax will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Area under the curve (AUC)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Area under the curve of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Volume of distribution (Vz)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Volume of distribution of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Total clearance (CL)
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Total clearance of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Elimination Half-life (t1/2).
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Elimination half-life of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
Tidsramme: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum Anti-Drug Antibodies will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Lisa Li, Bambusa Therapeutics, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. februar 2025

Primær fullføring (Antatt)

28. februar 2027

Studiet fullført (Antatt)

28. februar 2027

Datoer for studieregistrering

Først innsendt

30. januar 2025

Først innsendt som oppfylte QC-kriteriene

30. januar 2025

Først lagt ut (Faktiske)

5. februar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • BBT001-001

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .